Aim: To evaluate the efficacy and safety of a fixed-dose combination (FDC) of gemigliptin and rosuvastatin in patients with type 2 diabetes and dyslipidaemia.
| INTRODUCTION
Type 2 diabetes is a complex, chronic illness that can cause a number of serious long-term complications that are major causes of morbidity and mortality in diabetic patients. 1 The goal of diabetes management is to reduce the risk of these complications, and effective treatments are available to prevent the macro-and microvascular complications of diabetes. 2 Intensive glucose control has been shown to reduce microvascular complications of type 2 diabetes in previous large-scale trials, such as the UK Prospective Diabetes Study (UKPDS) and the
Action in Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation (ADVANCE). 3, 4 In particular, more intensive glucose control in newly diagnosed patients is associated with a significant decrease in the long-term risk of cardiovascular disease (CVD). 5 Based on extensive trial evidence, lipid-lowering therapy with statins and targeted antihypertensive treatment have also been shown to reduce the risk of CVD in patients with type 2 diabetes. [6] [7] [8] [9] [10] [11] Current guidelines for management of type 2 diabetes emphasize that patients require continuous medical care, with multifactorial risk reduction strategies beyond glycaemic control.
2,10
The DPP IV inhibitor gemigliptin is an anti-hyperglycaemic agent with well-recognized clinical efficacy in the treatment of diabetes. 12, 13 Rosuvastatin is a well-known inhibitor of HMG-CoA reductase and is used to treat dyslipidaemia. To simplify the medication regimen in patients who require these two drugs, a fixed-dose combination (FDC) of gemigliptin and rosuvastatin (Zemiro, LG Chem, Ltd, Seoul, Republic of Korea) has been developed. Adherence to statin therapy in patients with diabetes is reported to be poor, with a decrease from 87% in the first 3 months to less than 50% from 6 months onwards.
14 Fixed-dose combinations have been shown to improve medication adherence compared with free-drug component regimens. 15 This is important because adherence is a key factor associated with the effectiveness of pharmacological therapies, and is particularly critical for medications prescribed for chronic conditions. 16 The first FDC of these classes is sitagliptin (100 mg)/simvastatin (40 mg), which is marketed as Juvisync (Merck & Co., Inc., New Jersey). 17 However, there have been no published reports on the clinical efficacy and safety of the FDC of sitagliptin/simvastatin. There is accumulating evidence that high-intensity statin therapy reduces the risk of atherosclerotic cardiovascular disease (ASCVD) more than moderate-intensity statin therapy. High-intensity statins are recommended for patients with diabetes and with an increased risk of ASCVD. Simvastatin (40 mg) is a moderateintensity statin, while rosuvastatin (20 mg) is a high-intensity statin. 18 The FDC of gemigliptin/rosuvastatin is the first FDC of these classes with a high-intensity statin. In this study, we aimed to evaluate the efficacy and safety of this FDC in patients with type 2 diabetes and dyslipidaemia.
2 | METHODS
| Study design and participants
This study was a randomized, double-blind, multicentre, parallel group, phase 3 trial of FDC therapy with gemigliptin and rosuvastatin vs monotherapy with each drug in patients with type 2 diabetes and dyslipidaemia who were receiving concomitant metformin therapy. The study included three periods: a therapeutic lifestyle change (TLC) period of 2 weeks, a run-in period of 2 weeks, and a randomization period immediately followed by a treatment period (24 weeks). The TLC and run-in periods were sequential after a 4-week wash-out period in participants who were using an antilipidaemic agent. Participants continued to follow their pre-study dose regimen of metformin.
Patients were enrolled at 33 sites in Korea, and data were collected from study participants between April 30, 2014 and March 10, 2016.
Patients who were considered eligible at screening had type 2 diabetes (HbA1c ≥7% and ≤11%) and dyslipidaemia (low-density lipoprotein-cholesterol (LDL-C) ≥100 and ≤250 mg/dL), were 19 years or older, and had been receiving a stable dose of metformin (≥1000 mg/d) for at least 6 weeks prior to screening, or 2 weeks if patients were using an antilipidaemic agent within 4 weeks prior to screening. Patients who were using an antilipidaemic agent within 4 weeks before screening were considered eligible if they had an LDL-C ≥100 and ≤250 mg/dL after the 4-week wash-out period. Key exclusion criteria included use of oral antihyperglycemic drugs other than metformin, use of insulin or GLP-1 analogues, use of weight loss medications, a body mass index (BMI) higher than 40 kg/m 2 , creatinine clearance of less than 60 mL/min/1.73 m 2 , or a diagnosis of type 1 diabetes. We also excluded patients with a history of severe heart disease (angioplasty, stent placement, bypass surgery, myocardial infarction, unstable angina pectoris, New York Heart Association class III, IV congestive heart failure, or ventricular arrhythmia within 6 months before screening), those with a history of malignancy, and women who were pregnant or lactating. Full inclusion and exclusion criteria are available online in Table S1 , Supporting Information.
The study was approved by the independent institutional review boards of each participating centre before patient enrolment. Written informed consent was obtained from all participants. The trial (ClinicalTrials.gov, NCT02126358) was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.
| Randomization and masking
During the run-in period of 2 weeks, all participants received three placebo tablets once daily, and those who took more than 70% of the tablets were eligible for randomization. Eligible participants were randomly assigned by investigators in a 1:1:1 ratio to receive the FDC of gemigliptin and rosuvastatin (GEMI/ROSU FDC group), gemigliptin (GEMI group), or rosuvastatin (ROSU group) according to the random sequence generated by a statistician with use of an interactive web response system (IWRS). Randomization was stratified by baseline HbA1c (<8.5% and ≥8.5%). For maintenance of blinding, participants randomized to the GEMI/ROSU FDC group received two more placebo tablets, one matching gemigliptin and one matching rosuvastatin.
Likewise, participants randomly assigned to the GEMI or ROSU group also received two more placebo tablets matching the FDC of gemigliptin/rosuvastatin and rosuvastatin, respectively, or the FDC of gemigliptin/rosuvastatin and gemigliptin, respectively. All participants, study investigators, site staff and sponsor personnel were blinded to the treatment assignment.
| Procedure
Patients were instructed to take the medication as three tablets 
| Outcomes
Primary efficacy measures were changes in HbA1c and LDL-C from baseline to Week 24 between the GEMI/ROSU FDC and ROSU groups and between the GEMI/ROSU FDC and GEMI groups, respectively. Secondary efficacy measures were changes in HbA1C and LDL-C from baseline to Week 24 between the GEMI/ROSU FDC and GEMI groups and between the GEMI/ROSU FDC and ROSU groups, respectively. Tertiary efficacy endpoints were the proportion of participants achieving HbA1c <7.0% or <6.5% and LDL-C <100 mg/ dL and/or change in fasting plasma glucose, lipid parameters, body weight, homoeostasis model assessment (HOMA) for insulin resistance (HOMA-IR) and β-cell function (HOMA-β). Safety assessments included the monitoring of adverse events, vital signs (heart rate, blood pressure, body temperature), haematology, blood chemistry and urinalysis. We also monitored the occurrence of hypoglycaemia, defined as a blood glucose level of less than 70 mg/dL (plasma glucose measurement or finger-prick blood glucose measurement).
Severe hypoglycaemia was defined as an event that required the assistance of another individual.
| Statistical analyses
The sample size to demonstrate superiority of the FDC of gemigliptin/ rosuvastatin vs placebo with regard to mean change in HbA1c levels and percent change in LDL-C concentrations was determined using a significance level of 2.5% and a one-sided test. The planned enrolment was 95 patients per treatment group (total 285), which provided 90%
power to detect a mean difference of 0.64% in HbA1c levels and a 49.7% reduction in LDL-C concentrations vs placebo, assuming common standard deviations (SDs) of 1.21% and 13.3%, respectively. This calculation was based on the assumption of a 20% drop-out rate.
All participants who received at least one dose of trial medication, and for whom primary efficacy endpoints were measured at least once after randomization (Week 0) were included in efficacy analyses.
Safety analyses were performed in all randomly assigned patients who received at least one dose of trial medication. One-way ANOVA and paired t-tests were used to analyse normally distributed continuous 
| Role of funding source
The sponsor, LG Chem, Ltd, Seoul, Republic of Korea, and all authors agreed on the study design, protocol and statistical plan. An independent clinical research organization, blinded to the patient's study drug assignment, was responsible for trial management and data collection.
The sponsor was involved in data analysis but had no role in data interpretation or writing of the manuscript.
| RESULTS
We screened 551 patients, 290 of whom were eligible for randomization on the basis of inclusion and exclusion criteria: 96 were randomly assigned to the GEMI/ROSU FDC group; 97 to the GEMI group; and 97 to the ROSU group. Primary efficacy endpoints were not measured after randomization in six patients; these patients were therefore excluded from efficacy analyses. A total of 23 participants discontinued the study or study drug before 24 weeks, 10 from the GEMI/ ROSU FDC group, 7 from the GEMI group and 6 from the ROSU group (Figure 1 ).
Baseline demographics and clinical characteristics were well balanced among treatment groups, with the exception of LDL-C levels, which were higher in the GEMI group than in the GEMI/ROSU FDC or ROSU groups (Table 1) . Participants were middle aged (mean age, 56 years) and 50% were men. Mean duration of T2DM was 6.6 years and most participants were overweight (mean BMI, Trial profile. *The full analysis set consisted of all participants who received at least one dose of trial medication and for whom primary efficacy endpoints were measured at least once after randomization. Six randomly assigned participants, two in the gemigliptin/ rosuvastatin FDC group, three in the gemigliptin group and one in the rosuvastatin group, were without measurements of primary efficacy endpoints after randomization and were excluded from the full analysis set. The safety analysis set consisted of all participants who received at least one dose of the study drug. Abbreviation: FDC, fixed-dose combination the GEMI/ROSU FDC group achieved HbA1c targets of less than 7.0%, compared with 15 of 96 patients (15.6%) in the ROSU group ( Figure 4A) . Furthermore, 93.6% of participants treated with the FDC of gemigliptin/rosuvastatin achieved LDL-C targets of less than 100 mg/dL, compared with 14.9% in the GEMI group ( Figure 4B ).
Similar to the reduction in HbA1c, the proportion of participants who achieved HbA1c <7% or <6.5% was also greater in the GEMI group than in the GEMI/ROSU group, despite using the same dose of gemigliptin (50 mg) ( Figure 4A ). Least-square mean changes or mean percentage changes in other variables from baseline to 24 weeks are reported in Table 2 .
In this study, a total of 201 treatment-emergent adverse events were reported by 112 participants (38.6%). There were no significant differences in incidence rate of adverse events reported among the GEMI/ROSU FDC, GEMI and ROSU groups (45.8%, 30.9% and 39.2%, respectively) ( Table 3 ). Most adverse events were mild to moderate in intensity, and no hypoglycaemic episodes were reported.
| DISCUSSION
In this study, BALANCE, we showed that treatment with the FDC of gemigliptin/rosuvastatin for 24 weeks was effective in reducing both blood glucose and LDL-C in type 2 diabetic patients with dyslipidaemia who were not adequately treated with metformin. Among the patients treated with the FDC of gemigliptin/rosuvastatin, 44%
achieved HbA1c less than 7% and 94% achieved LDL-C less than 100 mg/dL by Week 24. Significant changes in HbA1c and LDL-C, compared with placebo, were apparent at Week 8, suggesting that the FDC of gemigliptin/rosuvastatin has a rapid and sustained effect.
The improvement in glycaemic control was probably driven by improved beta-cell function, as measured by HOMA-β, but not by insulin resistance, consistent with results from previous studies with other DPP-IV inhibitors. 19 In the BALANCE study, there was no difference in LDL-C reduction between the GEMI/ROSU FDC and ROSU groups. However, despite using the same dose of gemigliptin, the reduction in HbA1c was less marked in the GEMI/ROSU FDC group than in the GEMI group, by 0.47%, at 24 weeks. The proportion of participants who achieved HbA1c <7% or <6.5% was also lower in the GEMI/ROSU FDC group than in the GEMI group. We think that the reason for this difference in HbA1c reduction between these two groups is related to the use of a statin in the combined therapy. Many studies have shown the effect of statins on glucose. Randomized controlled trials (RCTs) and large observational studies have reported that statins can modestly raise blood glucose. 20 Several meta-analyses have shown a small but significant increase in new-onset diabetes in patients using various statins. 20, 21 It is interesting that the difference in HbA1c between the GEMI/ ROSU FDC and the GEMI groups was larger than that in other clinical trials. In a meta-analysis of nine RCTs involving patients with type 2 diabetes, the difference in mean HbA1c between the statin and control groups was only 0.17%. 22 This small difference is probably because most of the trials used low-to moderate-potency statins, with the exception of the DALI study. More intensive-dose statin therapy has been reported to be associated with greater risk of diabetes compared with moderate-dose statin therapy. 23 In the DALI study, the mean HbA1c of participants randomized to atorvastatin (80 mg) was 0.5% higher than that of participants randomized to the control group at the end of follow-up. 22 ROSU (20 mg), which was used in our study, is a high-potency statin, 18 and the difference in HbA1c
(0.47%) between the GEMI and GEMI/ROSU FDC groups was consistent with results of the DALI study.
We also observed a dose-dependent relationship between the statin dose and glucose in our study. There was no difference in HbA1c reduction between the GEMI/ROSU FDC and GEMI groups until rosuvastatin was up-titrated from 5 to 10 mg/d. However, after Current guidelines for the management of type 2 diabetes emphasize that patients with type 2 diabetes require continuous medical care, with multifactorial risk reduction strategies to reduce the risks of both cardiovascular and microvascular events. 2 Patients with type 2 diabetes often have more than three or four chronic conditions. 14 Thus, to implement multifactorial risk factor reduction strategies in type 2 diabetes, patients frequently need many kinds of medication, including those to control blood pressure, dyslipidaemia and other disorders. 2, 10 However, based on results of a number of studies, medication adherence declines as the number of drugs and dosing times per day increases. 14, 25 If the patients do not follow or adhere to the treatment plan faithfully, the intended beneficial effects of even the most carefully and scientifically based treatment plan will not be realized. 25 Indeed, many published studies have found that adherence to oral medication regimes in type 2 diabetes patients ranged from 65% to 85%. 14, 25 Adherence is a key factor associated with the effectiveness of pharmacological therapies and is particularly critical for medications prescribed for chronic conditions, 16 and fixed-dose combinations decrease the risk of medication non-adherence. A metaanalysis of more than 20 000 patients identified a 26% decrease in the risk of non-adherence associated with a fixed-dose combination compared with a free-drug combination regimen. 15 In terms of medication adherence, an FDC of gemigliptin and rosuvastatin could be an effective therapeutic strategy for patients with type 2 diabetes who require both a DPP IV inhibitor and statin therapy.
Given that there was a difference in HbA1c reduction between the GEMI/ROSU FDC and GEMI groups, despite receiving the same dose of gemigliptin, comparing the efficacy of the FDC of gemigliptin/ rosuvastatin with a free-drug combination of these two agents could have provided insight into the effects of rosuvastatin on glucose metabolism. However, we were unable to perform this comparison because we did not include a free-dose combination group in our study. Another limitation of our trial is the up-titration of rosuvastatin over the study period, which could have affected study outcomes. If rosuvastatin (5 mg) had been used from the beginning without dose adjustment, there would be no difference in HbA1c reduction between the GEMI/ROSU FDC and GEMI groups, or the magnitude of the difference would be different from that observed. Further studies are needed to evaluate the effect of different doses of rosuvastatin in the FDC.
In the BALANCE study, the FDC of gemigliptin/rosuvastatin was superior to rosuvastatin and gemigliptin in terms of reducing HbA1c
and LDL-C, respectively, in patients with type 2 diabetes and dyslipidaemia. There were no significant differences in adverse events among the GEMI/ROSU FDC, the GEMI and the ROSU groups, and no episode of hypoglycaemia was reported. The FDC of gemigliptin/ rosuvastatin is safe and effective in reducing both blood glucose and LDL-C levels and could be a good therapeutic choice in type 2 diabetic patients with dyslipidaemia.
